Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MGCD516

Known as: Multitargeted Kinase Inhibitor MGCD516 
An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, multitargeted kinase… Expand
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Broader (1)

sitravatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Review
2017
Review
2017
Targeting TRK family proteins in cancer
&NA; The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins, which are encoded by NTRK1, NTRK2 and… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
2017
2017
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases
Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Sarcomas are rare but highly aggressive mesenchymal tumors with a median survival of 10–18 months for metastatic disease… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2015
Review
2015
TRKing down an old oncogene in a new era of targeted therapy.
UNLABELLED The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has… Expand
  • figure 1
  • figure 2
2013
2013
In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.
Modification of drug delivery nanomaterials with affinity molecules that facilitate targeting, has rendered a new class of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells.
Dietary phytochemicals as adjuvants have been suggested to play important roles in enhancing chemotherapeutic potential owing to… Expand
2012
2012
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration…
One of the central unanswered questions in prostate cancer research is the significance of tyrosine kinase inhibitor (TKI… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)
563 Background: Autocrine and paracrine signaling involving VEGFR and PDGFR are implicated in angiogenesis and proliferation of… Expand
Highly Cited
2000
Highly Cited
2000
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
The scheduling of antifolate antitumor agents, including the new multitargeted autofolate LY231514 (MTA), with 5-fluorouracil was… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE